Single photon emission computerized tomography (SPECT) in detecting neurodegeneration in Huntington's disease. Nucl Med Commun 2002 Jan;23(1):13-8
Date
12/19/2001Pubmed ID
11748433DOI
10.1097/00006231-200201000-00004Scopus ID
2-s2.0-0036189153 (requires institutional sign-in at Scopus site) 11 CitationsAbstract
Single photon emission computerized tomography (SPECT) studies were performed on 34 manifest Huntington's disease (HD) patients at various stages of clinical pathology ranging from early chorea to late dystonia with or without signs of dementia and 12 pre-symptomatic patients with abnormal terminal CAG expansions. Thirty HD patients with obvious clinical signs and seven pre-symptomatic patients without signs or symptoms of HD displayed selective caudate hypoperfusion by direct visual inspection. Such qualitative, selective striatal hypoperfusion patterns can be indicative of early and persistent metabolic changes in striatal neuropathology. SPECT studies can be useful in documenting early pre-clinical changes in patients with abnormal terminal CAG expansions and in confirming the presence of caudate pathology in patients with clinical signs of HD.
Author List
Reynolds NC Jr, Hellman RS, Tikofsky RS, Prost RW, Mark LP, Elejalde BR, Lebel R, Hamsher KS, Swanson S, Benezra EEAuthor
Sara J. Swanson PhD Chief, Professor in the Neurology department at Medical College of WisconsinMESH terms used to index this publication - Major topics in bold
AdultAged
DNA
Female
Humans
Huntington Disease
Male
Middle Aged
Nerve Degeneration
Radiopharmaceuticals
Reverse Transcriptase Polymerase Chain Reaction
Tomography, Emission-Computed, Single-Photon